EUVIMEDEUVIMED entdecken
FallberichtOpen Access

The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report

Amber N Edinoff iD, David B Hathaway, David Martinez Garza, Jordan H Rosen, Joji Suzuki iD

The American Journal on Addictions · 2024

DOI: 10.1111/ajad.13516 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The American Journal on Addictions, 2024. Verfasst von Amber N Edinoff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts, USA. Hauptthemen laut MEDLINE: Alcoholism, Substance Withdrawal Syndrome, Glycerophospholipids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives The decision to initiate pharmacotherapy for alcohol withdrawal is typically based on examining self‐reported use of alcohol and symptoms of withdrawal. Phosphatidylethanol (PEth) is a biomarker that could aim in clinical decision‐making in withdrawal management.

Methods

This report describes three cases highlighting the potential clinical utility of PEth in caring for individuals at risk for alcohol withdrawal.

Results

Two of the cases received phenobarbital when their PEth showed that the risk of withdrawal was low and one case where PEth could have shown this was needed. The results were only available in a delayed fashion, however, could have been useful in informing clinical care. Discussion and Conclusion PEth can be a useful tool if available without delay. PEth can be used to quickly rule out alcohol withdrawal and avoid misdiagnoses and prolonged hospital stays. Scientific Significance This is a clinical case study available looking at PEth and withdrawal in hospitalized patients. It proposes that PEth can be used as a way to quickly rule out alcohol withdrawal to avoid misdiagnoses and the possibility of a prolonged hospital stay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlcoholismSubstance Withdrawal SyndromeGlycerophospholipidsHumansAlcohol DrinkingEthanolBiomarkers

Substanzen

phosphatidylethanolEthanolBiomarkersGlycerophospholipids

Autor:innen und Institutionen

  • Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts, USA.
  • Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Psychiatry, Massachusetts General Hospital, Boston, United States, USA.

ORCID-Profile: Amber N Edinoff, Joji Suzuki

Förderung

  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Edinoff, A. N., Hathaway, D. B., Martinez Garza, D., Rosen, J. H., & Suzuki, J. (2024). The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report. The American Journal on Addictions. https://doi.org/10.1111/ajad.13516

Vancouver

Edinoff AN, Hathaway DB, Martinez Garza D, Rosen JH, Suzuki J. The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report. The American Journal on Addictions. 2024. doi:10.1111/ajad.13516

BibTeX
@article{Edinoff2024,
  author = {Edinoff, Amber N and Hathaway, David B and Martinez Garza, David and Rosen, Jordan H and Suzuki, Joji},
  title = {The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report},
  journal = {The American Journal on Addictions},
  year = {2024},
  doi = {10.1111/ajad.13516}
}
Kostenlos starten →